Incyte
INCY
$0.00 (0.00%)
1D
1W
3M
1Y
5Y
ALL
Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company also conducts commercial and clinical development operations from its European headquarters in Morges, Switzerland, and Japanese office in Tokyo and Canadian headquarters in Montreal. It operates in two therapeutic areas, One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. The other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise is comprised of four products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib) and ICLUSIG (ponatinib), as well as other clinical development programs. Its Dermatology commercial franchise is comprised of OPZELURA (ruxolitinib) cream.
Open
Prior close
Today's high
Today's low
52 Week high
52 Week low
Business Wire • 7 days ago • INCY
Incyte Expands Presence in Delaware through Acquisition of Two Downtown Wilmington Office BuildingsZacks Investment Research • 11 days ago • INCY
Here's Why Incyte (INCY) Stock is Up More Than 7% in a WeekForbes • 13 days ago • INCY
How Does Incyte Stock's Decline During The 2022 Inflation Shock Compare With The 2008 Crash?Business Wire • 14 days ago • INCY
Incyte to Highlight Data From its Oncology Portfolio at the 2024 ASCO Annual Meeting and EHA2024 CongressInvestopedia • 15 days ago • INCY
S&P 500 Gains and Losses Today: Incyte Stock Pops on Buyback PlanCharts and pricing are provided for informational purposes only. The current market data is delayed up to 15 minutes. The accuracy of any market data displayed is not guaranteed.